Oxford Biomedica PLC Director/PDMR Shareholding (9813N)

TIDMOXB

RNS Number : 9813N

Oxford Biomedica PLC

22 May 2015

Oxford BioMedica plc Director's Share Purchase

Oxford, UK - 22 May 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 21 May 2015 one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

 
                                                             Interest after 
                                                              purchase 
-------------  --------------  ----------  ----------------  ---------------------------- 
  Director         Title         Price        Number of         Number       % of total 
    / PDMR                      per share   Ordinary Shares   of Ordinary      issued 
                                   (p)         acquired         Shares      share capital 
-------------  --------------  ----------  ----------------  ------------  -------------- 
               Non-executive 
Andrew Heath      director       10.6p         100,000        1,100,000        0.04% 
-------------  --------------  ----------  ----------------  ------------  -------------- 
 

The issued share capital of the Group is 2,568,145,765 1p ordinary shares.

- Ends -

 
 For further information, please 
  contact: 
  Oxford BioMedica plc:                    Tel: [phone] 
   John Dawson, Chief Executive Officer     783 000 
   Tim Watts, Chief Financial Officer 
  Consilium Strategic Communications       Tel: +44 (0)20 
   Mary-Jane Elliott/Matthew Neal/Chris     3709 5700 
   Welsh/Laura Thornton 
 

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector(R) IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBLGDUBGDBGUB